Loading...
•
Dec 31, 2021
Immunome Q4 2021 Earnings Report
Reported financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.
Key Takeaways
Immunome reported its financial results for the fourth quarter ended December 31, 2021, highlighting the FDA's safe-to-proceed notification for IMM-BCP-01 and the continued progress of IMM-ONC-01 towards an IND submission.
Received safe-to-proceed notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application.
Continued to progress IMM-BCP-01 towards Phase 1b Clinical Trial.
Made ongoing progress on Oncology Pipeline, including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint.
Analyzed IL-38 expression across nearly 60 tumor subtypes and confirmed a high frequency of expression in difficult to treat cancers.
Forward Guidance
Immunome is advancing its platform and programs, executing its regulatory, research, clinical and strategic plans and anticipated upcoming milestones for its platform and programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...